
    
      EO2463 Is an innovative cancer peptide therapeutic vaccine based on the homologies between
      tumor associated antigens and microbiome-derived peptides that will be administered alone and
      in combination with lenalidomide, rituximab, and lenalidomide/rituximab to generate safety
      and preliminary efficacy data in patients with indolent NHL
    
  